Clinical Trial Update: Persistency Study After Hib-CRM (Cross-Reacting Material)197 or Hib-TT (Tetanus Toxoid) Vaccines in Chinese Children [Phase 3]

View source ↗

Summary

Phase 3 persistency study evaluating Hib-CRM197 and Hib-TT Haemophilus influenzae type b vaccines in Chinese children has completed. Results were posted in 2015…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilus Influenzae Type Arthritis
• Haemophilus Influenzae Type Epiglottitis
• Haemophilus Influenzae Type Meningitis
• Haemophilus Influenzae Type Pneumonia

Drugs mentioned

• Hib-CRM197 vaccine (Haemophilus influenzae type b conjugate vaccine (CRM197 carrier))
• Hib-TT vaccine (Haemophilus influenzae type b conjugate vaccine (Tetanus toxoid carrier))

Snippet

Sponsor: Novartis Vaccines | Conditions: Meningitis, Epiglottitis, Pneumonia, Arthritis Caused by Haemophilus Influenzae Type b | Phase 3 | Status: COMPLETED | Results posted: 2015-11-09